Portal de investigación
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Maurel, J
- Alonso, V
- Escudero, P
- Fernandez-Martos, C
- Salud, A
- Mendez, M
- Gallego, J
- Rodriguez, JR
- Martin-Richard, M
- Fernandez-Plana, J
- Manzano, H
- Mendez, JC
- Zanui, M
- Falco, E
- Gil-Raga, M
- Feliu, J
- Garcia-Albeniz, X
- Torres, F
- Rojo, F
- Bellosillo, B
- Mendiola, M
- Fernandez, V
- Reig, O
- Claes, B
- Maertens, G
- Sablon, E
- Jacobs, B
- Montagut, C
Grupos
Abstract
PURPOSE RAS and BRAF mutations can be detected as a mechanism of acquired resistance in circulating tumor (ct) DNA in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. METHODS RAS and BRAF mutational status was assessed in ctDNA in a baseline plasma sample and a serum sample collected at the time of the last available determination (named secondary extraction) from patients with KRAS exon 2 wild-type metastatic colorectal cancer treated in two first-line prospective biomarker-designed clinical trials (PULSE, ClinicalTrials.gov identifier: NCT01288339; and POSIBA, ClincialTrials.gov identifier: NCT01276379). RESULTS Analysis of extended RAS and BRAF in tissue and plasma from 178 patients with KRAS exon 2 wild-type metastatic colorectal cancer showed a sensitivity of 64.1% and a specificity of 90%. The median overall survival (OS) of baseline patients with RAS and BRAF mutations in ctDNA was 22.3 months (95% CI, 15.6 to 29 months) and 8.9 months (95% CI, 6.3 to 11.4 months), respectively, which was significantly inferior to the median OS of 40.4 months (95% CI, 35.9 to 44.9 months) in two patients with wild-type disease (P < .001). Acquisition of RAS/BRAF mutations occurred in nine of 63 patients (14%) with progressive disease (PD; ie, blood draw within 1 month before PD or after PD) compared with six of 73 patients (8%) with no PD or blood extraction for ctDNA analysis before 1 month of PD (P= .47). Median OS in patients with RAS/BRAFacquisition was 23.9 months (95% CI, 19.7 to 27.9 months) compared with 40.6 months (95% CI, not reached to not reached) in patients who remained free of mutations (P= .016). CONCLUSION Our results confirm that baseline RAS and BRAF testing in ctDNA discriminates survival. The emergence of RAS/BRAF mutations has limited relevance for the time to progression to anti-epidermal growth factor receptor therapy. (C) 2019 by American Society of Clinical Oncology
Datos de la publicación
- ISSN/ISSNe:
- 2473-4284, 2473-4284
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1200/PO.18.00289
- PubMed:
- 35100697
- Factor de Impacto:
- 2,585 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JCO Precision Oncology LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 24
Documentos
- No hay documentos
Filiaciones
Cita
Maurel J,Alonso V,Escudero P,Fernandez C,Salud A,Mendez M,Gallego J,Rodriguez JR,Martin M,Fernandez J,Manzano H,Mendez JC,Zanui M,Falco E,Gil M,APARICIO J,Feliu J,Garcia X,Torres F,Rojo F,Bellosillo B,Mendiola M,Fernandez V,Reig O,Claes B,Maertens G,Sablon E,Jacobs B,Montagut C. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy. JCO Precis. Oncol. 2019. 3.